Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00230867 · ClinicalTrials.gov registry record · Phase 2

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

A Phase 2 study of Herpes Labialis, sponsored by Transport Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
1,800
Enrollment target
20
Study locations

NCT00230867 is a Phase 2 study of Herpes Labialis that has completed, run by Transport Pharmaceuticals. The registered enrollment target is 1,800 participants, above the 763-participant average among 6 other Herpes Labialis trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00230867, a Phase 2 study of Herpes Labialis, has completed, sponsored by Transport Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
1,800 participants
Enrollment target
20
Study locations

Study Summary

Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating. Iontophoresis uses electric current to enhance the delivery of drugs through the skin. This trial is testing a new iontophoretic device for the delivery of acyclovir cream to treat cold sores.

Conditions Studied

Herpes Labialis

Interventions

  • DEVICE iontophoretic acyclovir

Study Locations (20)

Arizona

  • Radiant Research Phoenix Southeast - Chandler
  • Radiant Research Phoenix - Phoenix
  • Radiant Research Scottsdale - Scottsdale

Florida

  • Radiant Research St. Petersburg - Pinellas Park
  • Radiant Research Stuart - Stuart
  • Radiant Research West Palm - West Palm Beach

California

  • Radiant Research San Diego - San Diego
  • Radiant Research Santa Rosa - Santa Rosa

Georgia

  • Radiant Research Atlanta West - Atlanta
  • Radiant Research Atlanta - Atlanta

Ohio

  • Radiant Research Cincinnati - Cincinnati
  • Pediatric Clinical Trials International - Columbus

Alabama

  • Radiant Research Birmingham - Birmingham

Idaho

  • Radiant Research Boise - Boise

Illinois

  • Radiant Research Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 1,800 participants
Start Date 2005-04
Est. Completion 2005-12
Phase Phase 2

Sponsor

Transport Pharmaceuticals

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00230867

The ClinicalTrials.gov registry entry for NCT00230867 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 763-participant average among 6 other Herpes Labialis trials with a reported enrollment target (136% higher). The listed sponsor is Transport Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Herpes Labialis appearing as the primary indexed condition, and to 1 intervention - of which iontophoretic acyclovir is the first listed.

NCT00230867 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, California.

Frequently Asked Questions

What is clinical trial NCT00230867 about?

NCT00230867 is a clinical study titled "Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis". Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating. Iontophoresis uses electric current to enhance the delivery of drugs through the ...

What is the current status of trial NCT00230867?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,800 participants. The study started on 2005-04. Estimated completion is 2005-12.

What conditions does trial NCT00230867 study?

This clinical trial studies the following conditions: Herpes Labialis.

What interventions are being tested in trial NCT00230867?

The interventions under investigation include: iontophoretic acyclovir (DEVICE).

Who is sponsoring clinical trial NCT00230867?

This trial is sponsored by Transport Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00230867 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Labialis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Herpes Labialis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.